COMPASS Pathways plc 8-K

What Happened

• On February 17, 2026, COMPASS Pathways plc filed an 8-K announcing that the Phase 3 COMP006 trial achieved its primary endpoint. Two fixed doses of COMP360 (25 mg) administered three weeks apart showed a statistically significant reduction in depression severity versus 1 mg at Week 6 (mean difference -3.8 points; 95% CI [-5.8, -1.8]; p<0.001). The company also cited prior COMP005 results (single 25 mg vs placebo) showing a mean treatment difference of -3.6 points (p<0.001).
• Compass said COMP360 demonstrated rapid onset (from the day after dosing) maintained through Week 6 in the 25 mg arms across both trials, and that retreatment (a second dose) was generally well tolerated.

Key Details

• Trial sizes and design: COMP006 Part A dosed 581 participants across North America and Europe (25 mg: n=296; 10 mg: n=142; 1 mg: n=143). COMP005 dosed 258 participants in the U.S. (25 mg: n=171; placebo: n=87).
• Efficacy at Week 6: COMP006 — 25 mg vs 1 mg mean difference -3.8 points (p<0.001); 39% of 25 mg participants achieved ≥25% MADRS reduction. COMP005 — single 25 mg previously showed -3.6 point difference (p<0.001); 25% achieved ≥25% MADRS reduction at Week 6.
• Safety: Most treatment-emergent adverse events (TEAEs) were mild/moderate and occurred on dosing days, with the majority resolving within ~24 hours. COMP006 Part A reported 6 treatment-emergent serious adverse events (SAEs) among 6 participants (2%); COMP005 reported 11 SAEs among 8 participants (5%). SAE suicidal ideation rate across both trials to date was <1%; one SAE of suicidal behavior occurred in the 1 mg arm of COMP006.
• Next steps/catalysts: COMP006 Part B (26‑week) data expected in early Q3 2026. Compass has requested a meeting with the FDA to discuss a potential rolling NDA submission and review.

Why It Matters

• These Phase 3 results provide a clearer efficacy signal for COMP360 in treatment‑resistant depression (TRD), showing statistically significant and clinically meaningful symptom reduction versus low-dose control. Positive late‑stage outcomes and upcoming 26‑week data are material near‑term milestones for the program.
• Safety information so far indicates most adverse effects are short‑lived and tied to dosing days, but SAEs and rare suicidal events are important risks investors should monitor. FDA engagement and the timing of the 26‑week readout are key regulatory and development catalysts to watch.